107 related articles for article (PubMed ID: 9087993)
1. Iron in the Parkinsonian substantia nigra.
Gerlach M; Double K; Riederer P; Hirsch E; Jellinger K; Jenner P; Trautwein A; Youdim MB
Mov Disord; 1997 Mar; 12(2):258-60. PubMed ID: 9087993
[No Abstract] [Full Text] [Related]
2. Iron in parkinsonian and control substantia nigra--a Mössbauer spectroscopy study.
Gałazka-Friedman J; Bauminger ER; Friedman A; Barcikowska M; Hechel D; Nowik I
Mov Disord; 1996 Jan; 11(1):8-16. PubMed ID: 8771061
[TBL] [Abstract][Full Text] [Related]
3. [Mossbauer spectroscopy of iron in substantia nigra in Parkinson disease and controls].
Friedman A; Bauminger ER; Gałazka-Friedman J; Barcikowska M; Suwalski J; Hechel D; Dymecki J; Nowik I
Neurol Neurochir Pol; 1994; 28(1 Suppl 1):145-55. PubMed ID: 8065540
[TBL] [Abstract][Full Text] [Related]
4. Iron and ferritin in substantia nigra in Parkinson's disease.
Jellinger KA; Kienzl E; Rumpelmaier G; Paulus W; Riederer P; Stachelberger H; Youdim MB; Ben-Shachar D
Adv Neurol; 1993; 60():267-72. PubMed ID: 8420142
[No Abstract] [Full Text] [Related]
5. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
[TBL] [Abstract][Full Text] [Related]
6. Iron and reactive oxygen species activity in parkinsonian substantia nigra.
Wypijewska A; Galazka-Friedman J; Bauminger ER; Wszolek ZK; Schweitzer KJ; Dickson DW; Jaklewicz A; Elbaum D; Friedman A
Parkinsonism Relat Disord; 2010 Jun; 16(5):329-33. PubMed ID: 20219408
[TBL] [Abstract][Full Text] [Related]
7. The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability.
Gibb WR; Fearnley JM; Lees AJ
Adv Neurol; 1990; 53():31-4. PubMed ID: 2173373
[No Abstract] [Full Text] [Related]
8. Is iron involved in pathogenesis of Parkinson's disease--Mössbauer spectroscopy study of substantia nigra in control and disease brains.
Friedman A; Bauminger ER; Gałazka-Friedman J; Barcikowska M; Hechel D; Nowik I; Marczewska M
Neurol Neurochir Pol; 1996; 30 Suppl 2():95-103. PubMed ID: 9100247
[No Abstract] [Full Text] [Related]
9. Diagnostic evaluation of the substantia nigra.
McRitchie DA; Halliday GM; Pamphlett R
Neuropathol Appl Neurobiol; 1996 Jun; 22(3):228-32. PubMed ID: 8804024
[TBL] [Abstract][Full Text] [Related]
10. What is the advantage of having melanin in parts of the central nervous system (e.g. substantia nigra)?
Costin GE
IUBMB Life; 2004 Jan; 56(1):47-9. PubMed ID: 14992380
[No Abstract] [Full Text] [Related]
11. [Study on the fiber connection of the substantia nigra].
Masuda S
Shinkei Kenkyu No Shimpo; 1968 Dec; 12(4):839-44. PubMed ID: 5753734
[No Abstract] [Full Text] [Related]
12. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
Youdim MB; Ben-Shachar D; Riederer P
Acta Neurol Scand Suppl; 1989; 126():47-54. PubMed ID: 2618593
[TBL] [Abstract][Full Text] [Related]
13. A new sensitive imaging biomarker for Parkinson disease?
Lang AE; Mikulis D
Neurology; 2009 Apr; 72(16):1374-5. PubMed ID: 19129504
[No Abstract] [Full Text] [Related]
14. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains.
Sofic E; Paulus W; Jellinger K; Riederer P; Youdim MB
J Neurochem; 1991 Mar; 56(3):978-82. PubMed ID: 1704426
[TBL] [Abstract][Full Text] [Related]
15. Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra.
Galazka-Friedman J; Bauminger ER; Koziorowski D; Friedman A
Biochim Biophys Acta; 2004 Mar; 1688(2):130-6. PubMed ID: 14990343
[TBL] [Abstract][Full Text] [Related]
16. Monomelic parkinsonian tremor caused by contralateral substantia nigra stroke.
Gonzalez-Alegre P
Parkinsonism Relat Disord; 2007 Apr; 13(3):182-4. PubMed ID: 16731026
[TBL] [Abstract][Full Text] [Related]
17. Iron metabolism and Parkinson's disease.
Hirsch EC; Faucheux BA
Mov Disord; 1998; 13 Suppl 1():39-45. PubMed ID: 9613717
[TBL] [Abstract][Full Text] [Related]
18. Iron-binding characteristics of neuromelanin of the human substantia nigra.
Double KL; Gerlach M; Schünemann V; Trautwein AX; Zecca L; Gallorini M; Youdim MB; Riederer P; Ben-Shachar D
Biochem Pharmacol; 2003 Aug; 66(3):489-94. PubMed ID: 12907248
[TBL] [Abstract][Full Text] [Related]
19. Individual dopaminergic neurons show raised iron levels in Parkinson disease.
Oakley AE; Collingwood JF; Dobson J; Love G; Perrott HR; Edwardson JA; Elstner M; Morris CM
Neurology; 2007 May; 68(21):1820-5. PubMed ID: 17515544
[TBL] [Abstract][Full Text] [Related]
20. Ultrastructural observations in Parkinsonism.
Roy S; Wolman L
J Pathol; 1969 Sep; 99(1):39-44. PubMed ID: 5359222
[No Abstract] [Full Text] [Related]
[Next] [New Search]
